Report: Gilead Is Considering Taking a Stake in Arcus Biosciences
Gilead Sciences (NASDAQ: GILD), a busy company these days, might be adding another significant investment to its agenda. An article published by Bloomberg after the market closed Wednesday, citing "people familiar with the matter," asserted that the biotech giant is mulling the purchase of a stake in Arcus Biosciences (NYSE: RCUS).
The two companies have had talks on the matter, but have also discussed merely entering into some development partnerships, according to the article's sources.
Arcus is a biotech that concentrates on oncology, an area of significant interest for Gilead. It has significantly boosted its presence in the segment, most recently by striking a deal to buy immuno-oncology specialist Forty Seven for $4.9 billion.
Source Fool.com
